PSEUDOTYPING PLASMID (Research Tool for Vaccine Development)
In May 2022, under the auspices of WHO’s COVID-19 Technology Access Pool (C-TAP), MPP signed two licensing agreements with the United States National Institutes of Health (NIH) for the development of 11 innovative therapeutics, early-stage vaccines and diagnostic tools for COVID-19.
Among these COVID-19 technologies is a research tool for vaccine development:
SARS-CoV-2 Pseudotyping Plasmid:
NIAID scientists developed a plasmid encoding spike proteins of SARS-CoV-2 variants. This research tool can be used to make pseudoviruses, which are harmless proxy viruses. Because SARS-CoV-2 is a potentially lethal and airborne virus, it must be handled in high-containment laboratories (Biosafety Level 3) that require special airflow, ventilation and decontamination procedures. Research on SARS-CoV-2 countermeasures can be conducted more expeditiously by using pseudoviruses in standard Biosafety Level 2 laboratories.
MPP invites interested developers anywhere in the world to express their interest in obtaining a sublicence for any of these technologies by submitting an e-mail to C-TAP-NIH@medicinespatentpool.org providing as much detail as possible as to what the developer intends to do with a sublicence.
|Aim of the licences
|To facilitate the manufacture and commercialisation of Covid-19 related health products and vaccines around the world
|One licence covers different patents and materials on technologies potentially relevant in the fight against COVID-19. The second licence specifically covers patents on the spike protein.
|Any product or vaccine that is covered by the Patents or Patent Applications or uses the Licensed Material.
|Field of use
|While one licence on the different technologies is granted for SARS-CoV-2 products for the WHO C-TAP program, the second licence, in relation to spike protein, refers to SARS-CoV-2 vaccines for the WHO C-TAP program.
|Continuing until the date the last Patent has lapsed, expired, or been invalidated
|Scope of the grant
|Non-exclusive right to grant royalty-bearing sublicences to develop the licensed patents/material into licensed products or vaccines, and to commercialise the licensed products or vaccines
|MPP invites interested developers anywhere in the world to express their interest in obtaining a sublicence for any of these technologies by submitting an e-mail to C-TAP-NIH@medicinespatentpool.org providing as much detail as possible as to what the developer intends to do with a sublicence